Kiessling, M K; Oberholzer, P A; Mondal, C; Karpova, M B; Zipser, M C; Lin, W M; Girardi, M; MacConaill, L E; Kehoe, S M; Hatton, C; French, L E; Garraway, L A; Polier, G; Süss, D; Klemke, C D; Krammer, P H; Gülow, K; Dummer, R (2011). High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood, 117(8):2433-2440.
Emery, C M; Vijayendran, K G; Zipser, M C; Sawyer, A M; Niu, L; Kim, J J; Hatton, C; Chopra, R; Oberholzer, P A; Karpova, M B; MacConaill, L E; Zhang, J; Gray, N S; Sellers, W R; Dummer, R; Garraway, L A (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 106(48):20411-20416.